Classical Hodgkin lymphoma · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Brentuximab vedotin and Dacarbazine Variant #01 | — | R 86 168 | 21d | — | — | — | — | — |
Brentuximab vedotin monotherapy Variant #01 | — | R 85 244 | 21d | ~25.6 mo | — | ~38 | ~R 3 239 268 PFS proxy · indirect | 2 |
ChlVPP/EVA Variant #01 Partial | — | R 4 896 | 28d | — | — | — | — | 1 |
VEPEMB Variant #01 Partial | — | R 3 562 | 28d | — | — | — | — | — |
ChlVPP Variant #01 Partial | — | R 2 327 | 28d | — | — | — | — | — |
PVAG Variant #01 | — | R 2 208 | 21d | — | — | — | — | — |
BEACOPP Variant #01 Partial | — | R 1 672 | 21d | — | — | — | — | — |
7 of 7 regimens shown